REFERENCES
- Drug Enforcement Administration. Department of Justice. Schedules of controlled substances: temporary placement of three synthetic phenethylamines into Schedule I. Final order. Fed Regist 2013; 78:68716–9.
- Harris County Institute of Forensic Sciences. Designer psychedelics: New class of designer drugs in Harris County. September 12, 2012.
- Nikolaou P, Papoutsis I, Stefanidou M, Spiliopoulou C, Athanaselis S. 2C-I-NBOMe, an “N-bomb” that kills with “Smiles”. Toxicological and legislative aspects. Drug Chem Toxicol 2014 [Epub ahead of print].
- Drug Enforcement Administration. 25I‑NBOMe, 25C‑NBOMe, and 25B‑NBOMe (Street names: N‑bomb, Smiles, 25I, 25C, 25B). Springfield, VA: Drug Enforcement Administration, 2013.
- Gonzalez-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007; 53:439–52.
- Halberstadt AL, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 2014; 77:200–7.
- Advisory Council on the Misuse of Drugs. ‘NBOMe’ compounds: A review of the evidence of use and harm. London, England; May 29, 2013:10–16. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261786/NBOMe_compounds_report.pdf (Accessed September 17, 2014).
- Ninnemann A, Stuart GL. The NBOMe series: a novel, dangerous group of hallucinogenic drugs. J Stud Alcohol Drugs 2013; 74:977–8.
- Kelly A, Eisenga B, Riley B, Judge B. Case series of 25I‑NBOMe exposures with laboratory confirmation. Clin Toxicol (Phila) 2012; 50:702.
- Hassan A. Lethal designer drug taking lives in streets of Houston. Houston Chronicle September 23, 2012; 111(346):B1,B4.
- Rose RS, Cumpston KL, Stromberg PE, Wills BK. Severe poisoning following self‑reported use of 25‑I, a novel substituted amphetamine. Clin Toxicol (Phila) 2012; 50:707–8.
- Caldicott DG, Bright SJ, Barratt MJ. NBOMe - a very different kettle of fish. Med J Aust 2013; 199:322–3.
- Hill SL, Doris T, Gurung S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila) 2013; 51:487–92.
- Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A. Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 2013; 6:764–9.
- Poklis JL, Devers KG, Arbefeville EF, Pearson JM, Houston E, Poklis A. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 2014; 234:e14-20. doi: 10.1016/j.forsciint.2013.10.015.
- Rose RS, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) 2013; 51:174–7.
- Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J Med Toxicol 2014; 10:45–50. doi: 10.1007/s13181-013-0314-y.
- Mowry JB, Spyker DA, Cantilena LR Jr, Bailey JE, Ford M. 2012 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol (Phila) 2013; 51:949–1229. doi: 10.3109/15563650.2013.863906.
- Forrester MB. 2C series phenethylamine derivative exposures in Texas. Subst Abus 2013; 34:81–2. doi: 10.1080/08897077.2012.715623.